Literature DB >> 23669101

Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures.

Xiaohong Cui1, Ronzo Lee, Stuart P Adler, Michael A McVoy.   

Abstract

Anti-cytomegalovirus (CMV) antibodies reduce the incidence of CMV transmission and ameliorate the severity of CMV-associated disease. Neutralizing activity, measured as the ability of antibodies to prevent entry of cell-free virus, is an important component of natural immunity. However, in vivo CMV amplification may occur mainly via spread between adjacent cells within tissues. Thus, inhibition of cell-to-cell spread may be important when evaluating therapeutic antibodies or humoral responses to infection or immunization. In vitro CMV cell-to-cell spread is largely resistant to antibodies in fibroblast cultures but sensitive in endothelial cell cultures. In the present study antibodies in CMV hyperimmuneglobulin or seropositive human sera inhibited CMV cell-to-cell spread in epithelial cell cultures. Spread inhibition activity was quantitated with a GFP reporter assay employing GFP-tagged epithelialtropic variants of CMV strains Towne or AD169. Measurement of spread inhibition provides an additional parameter for the evaluation of candidate vaccines or immunotherapeutics and to further characterize the role of antibodies in controlling CMV transmission and disease.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23669101      PMCID: PMC3774129          DOI: 10.1016/j.jviromet.2013.04.015

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  45 in total

1.  A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain).

Authors:  Mark A Jacobson; Stuart P Adler; Elizabeth Sinclair; Douglas Black; Anna Smith; Alice Chu; Ron B Moss; Mary K Wloch
Journal:  Vaccine       Date:  2009-01-23       Impact factor: 3.641

2.  Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells.

Authors:  Frances M Saccoccio; Anne L Sauer; Xiaohong Cui; Amy E Armstrong; El-Sayed E Habib; David C Johnson; Brent J Ryckman; Aloysius J Klingelhutz; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

Review 3.  Virus cell-to-cell transmission.

Authors:  Walther Mothes; Nathan M Sherer; Jing Jin; Peng Zhong
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

4.  Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection.

Authors:  Ekaterina Maidji; Giovanni Nigro; Takako Tabata; Susan McDonagh; Naoki Nozawa; Stephen Shiboski; Stefania Muci; Maurizio M Anceschi; Natali Aziz; Stuart P Adler; Lenore Pereira
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

5.  Human cytomegalovirus pUS27 G protein-coupled receptor homologue is required for efficient spread by the extracellular route but not for direct cell-to-cell spread.

Authors:  Christine M O'Connor; Thomas Shenk
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

6.  The impact of genome length on replication and genome stability of the herpesvirus guinea pig cytomegalovirus.

Authors:  Xiaohong Cui; Alistair McGregor; Mark R Schleiss; Michael A McVoy
Journal:  Virology       Date:  2009-01-26       Impact factor: 3.616

7.  Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition.

Authors:  Nicola Martin; Sonja Welsch; Clare Jolly; John A G Briggs; David Vaux; Quentin J Sattentau
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

8.  Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

Authors:  Annalisa Macagno; Nadia L Bernasconi; Fabrizia Vanzetta; Erica Dander; Antonella Sarasini; Maria Grazia Revello; Giuseppe Gerna; Federica Sallusto; Antonio Lanzavecchia
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

Review 9.  Findings and conclusions from CMV hyperimmune globulin treatment trials.

Authors:  Stuart P Adler; Giovanni Nigro
Journal:  J Clin Virol       Date:  2009-09-24       Impact factor: 3.168

10.  HCMV spread and cell tropism are determined by distinct virus populations.

Authors:  Laura Scrivano; Christian Sinzger; Hans Nitschko; Ulrich H Koszinowski; Barbara Adler
Journal:  PLoS Pathog       Date:  2011-01-13       Impact factor: 6.823

View more
  26 in total

1.  Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization.

Authors:  Xiaohong Cui; Stuart P Adler; Mark R Schleiss; Ravit Arav-Boger; Gail J Demmler Harrison; Michael A McVoy
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

Review 2.  Cytomegalovirus vaccines.

Authors:  Michael A McVoy
Journal:  Clin Infect Dis       Date:  2013-12       Impact factor: 9.079

3.  Persistent Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta.

Authors:  Takako Tabata; Matthew Petitt; June Fang-Hoover; Martin Zydek; Lenore Pereira
Journal:  Am J Pathol       Date:  2016-09-13       Impact factor: 4.307

4.  Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.

Authors:  Xiaohong Cui; Daniel C Freed; Dai Wang; Ping Qiu; Fengsheng Li; Tong-Ming Fu; Lawrence M Kauvar; Michael A McVoy
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

Review 5.  Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway.

Authors:  Thomas J Gardner; Domenico Tortorella
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-15       Impact factor: 11.056

6.  Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.

Authors:  Kirsten Schneider-Ohrum; Corinne Cayatte; Yi Liu; Zhaoti Wang; Alivelu Irrinki; Floro Cataniag; Nga Nguyen; Stacie Lambert; Hui Liu; Shahin Aslam; Greg Duke; Michael P McCarthy; Louise McCormick
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

Review 7.  Primary Human Cytomegalovirus (HCMV) Infection in Pregnancy.

Authors:  Horst Buxmann; Klaus Hamprecht; Matthias Meyer-Wittkopf; Klaus Friese
Journal:  Dtsch Arztebl Int       Date:  2017-01-27       Impact factor: 5.594

8.  Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.

Authors:  Marc Kirchmeier; Anne-Catherine Fluckiger; Catalina Soare; Jasminka Bozic; Barthelemy Ontsouka; Tanvir Ahmed; Abebaw Diress; Lenore Pereira; Florian Schödel; Stanley Plotkin; Charlotte Dalba; David Klatzmann; David E Anderson
Journal:  Clin Vaccine Immunol       Date:  2013-12-11

9.  Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.

Authors:  Mark R Schleiss; Ursula Berka; Elizabeth Watson; Mario Aistleithner; Bettina Kiefmann; Bastien Mangeat; Elizabeth C Swanson; Peter A Gillis; Nelmary Hernandez-Alvarado; Claudia Fernández-Alarcón; Jason C Zabeli; Daniel D Pinschewer; Anders E Lilja; Michael Schwendinger; Farshad Guirakhoo; Thomas P Monath; Klaus K Orlinger
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

10.  A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.

Authors:  Michael A McVoy; Ronzo Lee; Frances M Saccoccio; Jukka Hartikka; Larry R Smith; Rohit Mahajan; Jian Ben Wang; Xiaohong Cui; Stuart P Adler
Journal:  Vaccine       Date:  2015-10-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.